世界の卵巣がん診断市場は2023年に46億ドルと評価され、予測期間中に5.0%のCAGRで成長すると予想されます。卵巣がんの有病率の増加と早期診断と治療への注目の高まりが、市場の成長を促進する主な要因です。2023年現在、卵巣がんはすべての婦人科がんの中で最も死亡率が高く、高度な診断ツールが不可欠であることが浮き彫りになっています。米国がん協会は、2024年に米国で19,000人以上の患者が卵巣がんと診断されると推定しています。この統計は、医療従事者や研究者が早期発見と治療結果の改善に努めているため、卵巣がん診断市場の成長を後押ししています。
目次
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Ovarian Cancer Diagnostics Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Billion)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Ovarian Cancer Diagnostics Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
Chapter 4. Ovarian Cancer Diagnostics Market: Cancer Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Ovarian Cancer Diagnostics Market: Cancer Movement Analysis, USD Billion, 2023 & 2030
4.3. Epithelial Tumor
4.3.1. Epithelial Tumor Market Revenue Estimates and Forecasts, 2017 - 2030 (USD Billion)
4.4. Germ Cell Tumor
4.4.1. Germ Cell Tumor Revenue Estimates and Forecasts, 2017 - 2030 (USD Billion)
4.5. Stromal Cell Tumor
4.5.1. Stromal Cell Tumor Revenue Estimates and Forecasts, 2017 - 2030 (USD Billion)
4.6. Others
4.6.1. Others Revenue Estimates and Forecasts, 2017 - 2030 (USD Billion)
Chapter 5. Ovarian Cancer Diagnostics Market: Diagnosis Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Ovarian Cancer Diagnostics Market: Diagnosis Movement Analysis, USD Billion, 2023 & 2030
5.3. Imaging
5.3.1. Imaging Market Revenue Estimates and Forecasts, 2017 - 2030 (USD Billion)
5.4. Blood Test
5.4.1. Blood Test Market Revenue Estimates and Forecasts, 2017 - 2030 (USD Billion)
5.5. Biopsy
5.5.1. Biopsy Market Revenue Estimates and Forecasts, 2017 - 2030 (USD Billion)
5.6. Others
5.6.1. Others Market Revenue Estimates and Forecasts, 2017 - 2030 (USD Billion)
Chapter 6. Ovarian Cancer Diagnostics Market: End Use Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Ovarian Cancer Diagnostics Market: End Use Movement Analysis, (USD Billion, 2023 & 2030)
6.3. Hospital Laboratories
6.3.1. Hospital Laboratories Revenue Estimates and Forecasts, 2017 - 2030 (USD Billion)
6.4. Cancer Diagnostic Centers
6.4.1. Cancer Diagnostic Centers Revenue Estimates and Forecasts, 2017 - 2030 (USD Billion)
6.5. Research Institutes
6.5.1. Research Institutes Revenue Estimates and Forecasts, 2017 - 2030 (USD Billion)
6.6. Others
6.6.1. Others Market Revenue Estimates and Forecasts, 2017 - 2030 (USD Billion)
Chapter 7. Ovarian Cancer Diagnostics Market: Regional Estimates & Trend Analysis
7.1. Ovarian Cancer Diagnostics Market Share, By Region, 2023 & 2030, USD Billion
7.2. North America
7.2.1. North America Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2017 - 2030 (USD Billion)
7.2.2. U.S.
7.2.2.1. U.S. Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2017 - 2030 (USD Billion)
7.2.3. Canada
7.2.3.1. Canada Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2017 - 2030 (USD Billion)
7.2.4. Mexico
7.2.4.1. Mexico Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2017 - 2030 (USD Billion)
7.3. Europe
7.3.1. Europe Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2017 - 2030 (USD Billion)
7.3.2. U.K.
7.3.2.1. U.K. Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2017 - 2030 (USD Billion)
7.3.3. Germany
7.3.3.1. Germany Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2017 - 2030 (USD Billion)
7.3.4. France
7.3.4.1. France Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2017 - 2030 (USD Billion)
7.3.5. Italy
7.3.5.1. Italy Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2017 - 2030 (USD Billion)
7.3.6. Spain
7.3.6.1. Spain Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2017 - 2030 (USD Billion)
7.3.7. Denmark
7.3.7.1. Denmark Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2017 - 2030 (USD Billion)
7.3.8. Sweden
7.3.8.1. Sweden Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2017 - 2030 (USD Billion)
7.3.9. Norway
7.3.9.1. Norway Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2017 - 2030 (USD Billion)
7.4. Asia Pacific
7.4.1. Asia Pacific Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2017 - 2030 (USD Billion)
7.4.2. Japan
7.4.2.1. Japan Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2017 - 2030 (USD Billion)
7.4.3. China
7.4.3.1. China Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2017 - 2030 (USD Billion)
7.4.4. India
7.4.4.1. India Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2017 - 2030 (USD Billion)
7.4.5. South Korea
7.4.5.1. South Korea Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2017 - 2030 (USD Billion)
7.4.6. Australia
7.4.6.1. Australia Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2017 - 2030 (USD Billion)
7.4.7. Thailand
7.4.7.1. Thailand Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2017 - 2030 (USD Billion)
7.5. Latin America
7.5.1.1. Latin America Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2017 - 2030 (USD Billion)
7.5.2. Brazil
7.5.2.1. Brazil Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2017 - 2030 (USD Billion)
7.5.3. Argentina
7.5.3.1. Argentina Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2017 - 2030 (USD Billion)
7.6. Middle East and Africa
7.6.1. Middle East and Africa Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2017 - 2030 (USD Billion)
7.6.2. Saudi Arabia
7.6.2.1. Saudi Arabia Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2017 - 2030 (USD Billion)
7.6.3. South Africa
7.6.3.1. South Africa Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2017 - 2030 (USD Billion)
7.6.4. UAE
7.6.4.1. UAE Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2017 - 2030 (USD Billion)
7.6.5. Kuwait
7.6.5.1. Kuwait Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2017 - 2030 (USD Billion)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
8.4.1. F. Hoffmann-La Roche AG
8.4.1.1. Participant’s Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Recent Developments/ Strategic Initiatives
8.4.2. Johnson & Johnson Services, Inc.
8.4.2.1. Participant’s Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Recent Developments/ Strategic Initiatives
8.4.3. GlaxoSmithKline Plc
8.4.3.1. Participant’s Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Recent Developments/ Strategic Initiatives
8.4.4. AstraZeneca Plc
8.4.4.1. Participant’s Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Recent Developments/ Strategic Initiatives
8.4.5. Siemens Healthcare GmbH
8.4.5.1. Participant’s Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Recent Developments/ Strategic Initiatives
8.4.6. Abbott
8.4.6.1. Participant’s Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Recent Developments/ Strategic Initiatives
8.4.7. Thermo Fisher Scientific
8.4.7.1. Participant’s Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Recent Developments/ Strategic Initiatives
8.4.8. Bio-Rad Laboratories, Inc
8.4.8.1. Participant’s Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Recent Developments/ Strategic Initiatives
8.4.9. Quest Diagnostics Incorporated
8.4.9.1. Participant’s Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Recent Developments/ Strategic Initiatives
8.4.10. Illumina, Inc
8.4.10.1. Participant’s Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Recent Developments/ Strategic Initiatives
